β-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression

Nature

Volumn 433, Issue 7021, 2005, Pages 73-77

  Rothstein, Jeffrey D ^a   Patel, Sarjubhai ^a   Regan, Melissa R ^a   Haenggeli, Christine ^a   Huang, Yanhua H ^a   Bergles, Dwight E ^a   Jin, Lin ^a   Hoberg, Margaret Dykes ^a   Vidensky, Svetlana ^a   Chung, Dorothy S ^a   Shuy, Vang Toan ^a   Bruijn, Lucie I ^b   Su, Zao Zhong ^c   Gupta, Pankaj ^c   Fisher, Paul B ^c  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ALS Association   (United States)

^c Dept Pathol Neurosurg and Urol ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMISTRY; DEGRADATION; DERIVATIVES; DISEASES; GENES; MATHEMATICAL MODELS; MUSCLE; NEUROLOGY; PHYSIOLOGY; PROTEINS;

AMYOTROPHIC LATERAL SCLEROSIS (ALS); GLUTAMATE TRANSPORTER (GLT1); NEUROPROTECTION; NEUROTRANSMITTERS;

ANTIBIOTICS;

AMOXICILLIN; BUCLADESINE; CEFTRIAXONE; DIMETHYL SULFOXIDE; GLUTAMATE TRANSPORTER; GLUTAMIC ACID; GLYCINE; VANCOMYCIN;

ANTIBIOTICS;

AMYOTROPHIC LATERAL SCLEROSIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN DEGENERATION; BRAIN ISCHEMIA; CONTROLLED STUDY; DRUG ACTIVITY; DRUG INHIBITION; DRUG POTENCY; GENE ACTIVATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; MUSCLE STRENGTH; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANIMALS; ANTI-BACTERIAL AGENTS; BETA-LACTAMS; CEFTRIAXONE; CELL COUNT; CELLS, CULTURED; CENTRAL NERVOUS SYSTEM; DRUG EVALUATION, PRECLINICAL; EXCITATORY AMINO ACID TRANSPORTER 2; GENE EXPRESSION REGULATION; GENES, REPORTER; ISCHEMIC PRECONDITIONING; MICE; MICE, TRANSGENIC; MOTOR NEURONS; NEUROPROTECTIVE AGENTS; PENICILLINS; PROMOTER REGIONS (GENETICS); RNA, MESSENGER; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

ANIMALIA; BACTERIA (MICROORGANISMS);

EID: 19944428649     PISSN: 00280836     EISSN: None     Source Type: Journal    
DOI: 10.1038/nature03180     Document Type: Article

References (26)

1. Rothstein, J. D. et al. Knockout of glutamate transporters reveals a major role for astroglial transport in excitotoxicity and clearance of glutamate. Neuron 16, 675-686 (1996).
2. Danbolt, N. C. Glutamate uptake. Prog. Neurobiol. 65, 1-105 (2001).
3. Rothstein, J. D., Van Kammen, M., Levey, A. I., Martin, L. J. & Kuncl, R. W. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann. Neurol. 38, 73-84 (1995).
4. Rao, V. L. et al. Antisense knockdown of the glial glutamate transporter GLT-1, but not the neuronal glutamate transporter EAAC1, exacerbates transient focal cerebral ischemia-induced neuronal damage in rat brain. J. Neurosci. 21, 1876-1883 (2001).
5. Ye, Z. C., Rothstein, J. D. & Sontheimer, H. Compromised glutamate transport in human glioma cells: reduction-mislocalization of sodium-dependent glutamate transporters and enhanced activity of cystine-glutamate exchange. J. Neurosci. 19, 10767-10777 (1999).
6. Sepkuty, J. P. et al. A neuronal glutamate transporter contributes to neurotransmitter GABA synthesis and epilepsy. J. Neurosci. 22, 6372-6379 (2002).
7. Su, Z. Z. et al. Insights into glutamate transport regulation in human astrocytes: cloning of the promoter for excitatory amino acid transporter 2 (EAAT2). Proc. Natl Acad. Sci. USA 100, 1955-1960 (2003).
8. Goodman, L. S., Hardman, J. G., Limbird, L. E. & Gilman, A. G. Goodman & Gilman's The Pharmacological Basis of Therapeutics (McGraw-Hill Medical Pub. Division, New York, 2001).
9. Tanaka, K. et al. Epilepsy and exacerbation of brain injury in mice lacking the glutamate transporter GLT-1. Science 276, 1699-1702 (1997).
10. Watase, K. et al. Motor discoordination and increased susceptibility to cerebellar injury in GLAST mutant mice. Eur. J. Neurosci. 10, 976-988 (1998).
11. Rothstein, J. D., Jin, L., Dykes-Hoberg, M. & Kuncl, R. W. Chronic inhibition of glutamate uptake produces a model of slow neurotoxicity. Proc. Natl Acad. Sci. USA 90, 6591-6595 (1993).
12. Chandrasekar, P., Rolston, K., Smith, B. & LeFrock, J. Diffusion of ceftriaxone into the cerebrospinal fluid of adults. J. Antimicrob. Chemother. 14, 427-430 (1984).
13. Nau, R. et al. Passage of cefotaxime and ceftriaxone into cerebrospinal fluid of patients with uninflamed meninges. Antimicrob. Agents Chemother. 37, 1518-1524 (1993).
14. Kazragis, R., Dever, L., Jorgensen, J. & Barbour, A. In vivo activities of ceftriaxone and vancomycin against Borrelia spp. in the mouse brain and other sites. Antimicrob. Agents Chemother. 38, 2632-2636 (1996).
15. Chen, W. et al. Expression of a variant form of the glutamate transporter GLT1 in neuronal cultures and in neurons and astrocytes in the rat brain. J. Neurosci. 22, 2142-2152 (2002).
16. +-dependent glutamate transporters by cyclic AMP analogs and neurons. Mol. Pharmacol. 53, 355-369 (1998).
17. Guo, H. et al. Increased expression of the glial glutamate transporter EAAT2 modulates excitotoxicity and delays the onset but not the outcome of ALS in mice. Hum. Mol. Genet. 12, 2519-2532 (2003).
18. Romera, C. et al. In vitro ischemic tolerance involves upregulation of glutamate transport partly mediated by the TACE/ADAM17-tumor necrosis factor-alpha pathway. J. Neurosci. 24, 1350-1357 (2004).
19. Spalloni, A. et al. Cu/Zn-superoxide dismutase (GLY93 → ALA) mutation alters AMPA receptor subunit expression and function and potentiates kainate-mediated toxicity in motor neurons in culture. Neurobiol. Dis. 15, 340-350 (2004).
20. Canton, T. et al. RPR 119990, a novel alpha-amino-3-hydroxy-5-methyl-4- isoxazolepropionic acid antagonist: synthesis, pharmacological properties, and activity in an animal model of amyotrophic lateral sclerosis. J. Pharmacol. Exp. Ther. 299, 314-322 (2003).
21. Rothstein, J. D. & Kuncl, R. W. Neuroprotective strategies in a model of chronic glutamate-mediated motor neuron toxicity. J. Neurochem. 65, 643-651 (1995).
22. Kaspar, B. K., Llado, J., Sherkat, N., Rothstein, J. D. & Gage, F. H. Retrograde viral delivery of IGF-1 prolongs survival in a mouse ALS model. Science 301, 839-842 (2003).
23. Drachman, D. B. et al. Cyclooxygenase 2 inhibition protects motor neurons and prolongs survival in a transgenic mouse model of ALS. Ann. Neurol 52, 771-778 (2002).
24. Howland, D. S. et al. Focalloss of the glutamate transporter EAAT2 in a transgenic rat model of SOD1 mutant-mediated amyotrophic lateral sclerosis (ALS). Proc. Natl Acad. Sci. USA 99, 1604-1609 (2002).
25. Rothstein, J. D., Martin, L. J. & Kuncl, R. W. Decreased glutamate transport by the brain and spinal cord in amyotrophic lateral sclerosis. N. Engl. J. Med. 326, 1464-1468 (1992).
26. Gong, S., Yang, X. W., Li, C. & Heintz, N. Highly efficient modification of bacterial artificial chromosomes (BACs) using novel shuttle vectors containing the R6Kgamma origin of replication. Genome Res. 12, 1992-1998 (2002).